Back to News
Market Impact: 0.2
B. Riley Securities Initiates Coverage of Precigen at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
B. Riley Securities initiated coverage of Precigen (NASDAQGS:PGEN) on September 25, 2026, with a Buy recommendation. Precigen is a U.S. biotechnology company developing gene and cell therapies; the article provides no price target, financial estimates, or clinical-update details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PGEN0.45
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Beware borrowing costs: The jump in yields could hit these debt-laden stocks the most
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- Akamai stock is surging. A $12 billion Anthropic deal reveals its powerful edge over cloud providers.